We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01273935
First Posted: January 11, 2011
Last Update Posted: January 11, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ruhr University of Bochum
January 10, 2011
January 11, 2011
January 11, 2011
January 2010
Not Provided
Result of platelet function test
Aggregometry result of antiplatelet therapy
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke
Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke
The aim of this study is to evaluate the low-response prevalence of early antiplatelet therapy and to test the influence of different aspirin dosages in patients with acute ischemic strokes (AIS).
Antiplatelet agents are important therapeutic options in treating patients with acute ischemic strokes to prevent recurrent ischemic events or death. The aim of this study was to evaluate the low-response prevalence of early antiplatelet therapy and the influence of different aspirin dosages in patients with acute ischemic strokes (AIS).
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Patients admitted to the stroke unit
Test the Efficacy of Antiplatelet Regimes in Acute Stroke
Not Provided
  • Responder
    Responder versus Non-Responder as a result of platelet function test
  • Non-Responder
    According to the result of platelet function test
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
December 2010
Not Provided

Inclusion Criteria:

  • suspected acute cerebrovascular ischemic events and patients who were admitted to the stroke unit where antiplatelet therapy was initiated

Exclusion Criteria:

  • severe liver disorders, current gastrointestinal disorders, congestive heart failure, life-threatening malignancies and a personal or family history of bleeding disorders
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01273935
MevesASS01
No
Not Provided
Not Provided
Medical Faculty Ruhr-University Bochum, Dekanat der Medizinischen Fakultät, Forschungsreferat - FoRUM
Ruhr University of Bochum
Not Provided
Principal Investigator: Saskia H Meves, MD Department of Neurology, St. Josef - Hospital, Bochum, Germany
Ruhr University of Bochum
January 2010